The new British consensus guidelines on vision loss following fillers shift the focus from the mere fact of the rare risk to the clinic's readiness to act without delay. It’s not just about injection technique, but about the patient’s journey, informed consent, emergency kit in the clinic, and understanding which initial steps are permissible before transferring to an emergency department. This approach is precisely articulated in the new British consensus guidelines published in the Aesthetic Surgery Journal.
The document was prepared by a multidisciplinary working group that included specialists in aesthetic medicine, emergency ophthalmology, oculoplastics, retinal surgery, nursing practice, and pharmacy. In the abstract on PubMed, the authors explicitly state that these guidelines focus on emergency measures, pathways to specialized care, improving the informed consent process, and raising awareness of visual complications. This is an important distinction: the document does not attempt to re-explain the entire problem from scratch but provides clinicians with a practical framework for action in situations where time is of the essence.
Why vision loss after fillers is back in the professional spotlight
The reason is simple: the number of filler procedures is increasing, and with it, the number of reported complications. The guidelines provide a telling dynamic: if in 2015, 98 cases of vision impairment after filler injections were described in the literature, by 2018, there were already 146, and by March 2023, 511. For the professional community, this means that even a rare complication can no longer be viewed as a purely theoretical scenario or an exception that will never occur in real practice.
The mechanism of complication is described quite directly in the document. Unintentional intravascular injection of a tissue filler, most often a hyaluronic acid-based product, into the facial vascular system can lead to retrograde embolization and blockage of blood flow in arteries related to the eye. This is why vision loss after fillers is not a "cosmetic side effect" but a genuine vascular event. The specific artery that is blocked determines the nature of the visual deficit, accompanying symptoms, and the prognosis for the patient.
The guidelines specifically emphasize that such a complication usually occurs immediately or within the first 10 minutes after injection. Many cases are severe from the outset. In the aggregated data referenced by the authors, 62.7% of patients had no light perception, ptosis was described in 56.2% of cases, ophthalmoplegia in 44.1%, and signs of central nervous system involvement in nearly 20% of cases. These figures sharply change the perception of the topic: it is not about temporary discomfort or an "unpleasant but reversible" side effect, but a complication that can have catastrophic consequences.
The text also explicitly states that visual recovery is variable, and the most important prognostic factor remains the degree of vision loss at the first examination. For the clinic, this means only one thing: the value lies not only in the injection technique before the complication but also in the speed of recognizing the event afterward. Time lost in hesitation, complacency, or delay in transferring the patient has real clinical significance in such a scenario.
What the new British consensus guidelines recommend
The strength of the document is that it is built not around abstract considerations but around practical questions. Does the clinic know where exactly to direct such a patient? Is an emergency kit needed? Should the risk of vision loss be explicitly mentioned during informed consent? What actions are permissible in the first minutes, and what only creates dangerous delays? These are the questions discussed by the multidisciplinary group convened in 2024. Formulations were agreed upon through structured voting, with a consensus threshold of over 75% agreement.
One of the main practical conclusions is stated harshly and clearly: if there is suspicion of damage to the visual system or the central nervous system, the patient should be delivered without delay to the nearest emergency department. This principle may seem simple, but it is one of the key shifts in the guidelines. The logic here is that a specialized ophthalmological unit is not always the fastest and safest first route, especially if the clinical picture may extend beyond just ocular symptoms and have a neurological component.
An equally important part of the document concerns the readiness of the clinic itself. The authors believe that doctors working with tissue fillers should have an emergency kit for visual and ischemic complications at hand, as well as simple instructions for recognizing symptoms and a basic action plan. The article explicitly mentions the following components of the kit:
- timolol 0.5% eye drops
- paper bag for rebreathing
- aspirin 300 mg
- hyaluronidase at least 7500 IU, if the specialist is trained in its use
Importantly, the authors speak not only about the presence of medications as such. They recommend regularly checking the expiration dates of the kit's contents, having ready simple action schemes, and training the team to recognize symptoms of a vascular event. Otherwise, even a well-equipped emergency kit risks remaining a decorative element "just in case," rather than a real part of the safety system. This is one of the most valuable insights of the document: the problem is not solved by the mere presence of hyaluronidase or eye drops. It is solved only when the entire team understands when exactly the emergency protocol is triggered and who does what in the first minutes.
Another major block of changes concerns informed consent. The authors unanimously believe that before filler injections, the patient should be informed about the risk of vision loss, and the risk should be described as "rare," rather than attempting to name an exact figure for a specific area or technique. The reason is that the real scale of the risk is difficult to calculate due to underreporting, heterogeneous diagnostics, lack of standardized data collection, and other limitations. The document also notes that during consent, it is worth considering mentioning the risk of stroke. This is an unpleasant but honest part of modern practice, especially when it comes to complications that can extend beyond just ocular symptoms.
The first minutes after suspected vision loss: what is permissible and what should not be overestimated
The consensus guidelines allow for several initial non-invasive actions that can be performed in the clinic before transportation. Their goal is to try to shift the embolus further into a more peripheral part of the ophthalmic vascular bed, thereby giving a chance for retinal perfusion recovery. Such measures in the document include ocular massage, rebreathing into a paper bag, and timolol 0.5% drops in the affected eye.
But this is where the document sounds particularly sober. The authors acknowledge that there is no high-level evidence base for such measures. They can be tried due to relative safety and potential benefit, but none of these steps should create a significant delay before delivering the patient to the nearest emergency department. This is one of the most important thoughts in the entire document: initial actions should support the patient's route, not replace it.
In practical terms, this means that sudden vision deterioration, complete or partial vision loss, severe pain, ptosis, eye movement disorders, pallor, or other ischemic skin changes in the periocular area cannot be perceived as a temporary reaction to the procedure. These are symptoms that should trigger an emergency protocol, not observation "for a few more minutes." Adding to this, that approximately one-fifth of cases may have stroke-like features, it becomes clear why the document strongly emphasizes the speed of escalation.
The recommendations also warn against actions that may only give the appearance of active intervention. The authors explicitly write that measuring visual acuity, pupil reactions, or eye motility should not delay patient transfer if these tests do not change the immediate strategy. Similarly, routine invasive procedures like anterior chamber paracentesis are not supported due to limited evidence of benefit and the risk of additional complications. Thus, the recommendations not only say "something must be done," but also outline the boundaries of useful activity.
The role of hyaluronidase and what it means for the doctor and patient
Most professional discussions traditionally arise around hyaluronidase, and the new British consensus guidelines openly acknowledge this. The document does not present it as a universal solution. Its use can only be considered when the suspected complication is specifically related to a hyaluronic acid-based filler. In other words, it is a tool for a specific scenario, not a standard response to any vision loss after injection.
The text explicitly states that periocular hyaluronidase may theoretically be beneficial for visual prognosis, so it can be tried if the doctor is confident in the technique and if it does not create a delay before patient transfer. Conversely, retrobulbar or peribulbar administration is not supported due to weak evidence and specific risks, including the risk of eye perforation. For practice, this is an important signal: hyaluronidase remains part of the conversation, but its role has become much more restrained and precise.
Another strong point of these recommendations is that they honestly outline their own limits. They do not promise guaranteed vision recovery. On the contrary, the authors explicitly write that visual recovery is variable, and the most important prognostic factor remains the degree of vision loss at the first examination. This is what makes the document mature and useful: it does not create the illusion of a "rescue recipe," but provides pragmatic steps for the first line of help.
“We wrote this peer-reviewed publication to help practitioners performing injections understand the risk of vision loss following dermal filler administration and provide guidance on managing such cases.”
Mr. James Neffendorf, consultant ophthalmologist and vitreoretinal surgeon, in a comment for Aesthetics Journal.
For the doctor, the main change is that vision loss after fillers should no longer exist in the mind as a "very rare scare story." It is a scenario for which the clinic must be prepared in advance. In practical terms, this means four things: realistic informed consent, a clear route to the emergency department, an emergency kit in the clinic, and training the team to recognize symptoms without losing time.
For the patient, the main conclusion is also quite straightforward: the safety of the procedure depends not only on the brand of filler or the clinic's popularity. It depends on anatomical knowledge, technique, the doctor's readiness to act in a vascular complication, and an honest discussion about risks before the injection. This is why these consensus guidelines are important not only for specialists—they also change the standard of responsible communication with the patient.